Abstract
Dupilumab is a monoclonal antibody that blocks IL-4 and Il-13 activity. It is approved for use in children age 5+ for asthma and atopic dermatitis, and was recently approved for treatment of eosinophilic esophagitis (EoE). We examined real-world use and efficacy of this medicine in our pediatric allergy clinic.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
